These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

371 related items for PubMed ID: 19683826

  • 1. The prognostic significance of ERCC1, BRCA1, XRCC1, and betaIII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection.
    Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH.
    Lung Cancer; 2010 Jun; 68(3):478-83. PubMed ID: 19683826
    [Abstract] [Full Text] [Related]

  • 2. Differences in the expression profiles of excision repair crosscomplementation group 1, x-ray repair crosscomplementation group 1, and betaIII-tubulin between primary non-small cell lung cancer and metastatic lymph nodes and the significance in mid-term survival.
    Kang CH, Jang BG, Kim DW, Chung DH, Kim YT, Jheon S, Sung SW, Kim JH.
    J Thorac Oncol; 2009 Nov; 4(11):1307-12. PubMed ID: 19745766
    [Abstract] [Full Text] [Related]

  • 3. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z, Qing Y, Guan W, Li M, Peng Y, Zhang S, Xiong Y, Wang D.
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [Abstract] [Full Text] [Related]

  • 4. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 5. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study).
    Toffart AC, Timsit JF, Couraud S, Merle P, Moro-Sibilot D, Perol M, Mastroianni B, Souquet PJ, Girard N, Jeannin G, Romand P, Chatellain P, Vesin A, Brambilla C, Brambilla E.
    Lung Cancer; 2014 Feb; 83(2):182-8. PubMed ID: 24388706
    [Abstract] [Full Text] [Related]

  • 6. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
    Okuda K, Sasaki H, Dumontet C, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.
    Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
    [Abstract] [Full Text] [Related]

  • 7. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy.
    Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K.
    Cancer; 2008 Sep 15; 113(6):1379-86. PubMed ID: 18623378
    [Abstract] [Full Text] [Related]

  • 8. ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer.
    Fujii T, Toyooka S, Ichimura K, Fujiwara Y, Hotta K, Soh J, Suehisa H, Kobayashi N, Aoe M, Yoshino T, Kiura K, Date H.
    Lung Cancer; 2008 Mar 15; 59(3):377-84. PubMed ID: 17905465
    [Abstract] [Full Text] [Related]

  • 9. Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy.
    Li J, Li ZN, Yu LC, Bao QL, Wu JR, Shi SB, Li XQ.
    Lung Cancer; 2010 Jul 15; 69(1):116-22. PubMed ID: 19875192
    [Abstract] [Full Text] [Related]

  • 10. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H, Stathopoulos E, Fiolitaki G, Koutsopoulos A, Voutsina A, Georgoulias V, Mavroudis D.
    Lung Cancer; 2013 Nov 15; 82(2):324-9. PubMed ID: 23993732
    [Abstract] [Full Text] [Related]

  • 11. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with a combination of cisplatin/docetaxel and concurrent thoracic irradiation.
    Azuma K, Sasada T, Kawahara A, Hattori S, Kinoshita T, Takamori S, Ichiki M, Imamura Y, Ikeda J, Kage M, Kuwano M, Aizawa H.
    Cancer Chemother Pharmacol; 2009 Aug 15; 64(3):565-73. PubMed ID: 19123003
    [Abstract] [Full Text] [Related]

  • 12. Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
    Joerger M, deJong D, Burylo A, Burgers JA, Baas P, Huitema AD, Beijnen JH, Schellens JH.
    Lung Cancer; 2011 Nov 15; 74(2):310-7. PubMed ID: 21529986
    [Abstract] [Full Text] [Related]

  • 13. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
    Ting S, Mairinger FD, Hager T, Welter S, Eberhardt WE, Wohlschlaeger J, Schmid KW, Christoph DC.
    Clin Lung Cancer; 2013 Sep 15; 14(5):558-567.e3. PubMed ID: 23810210
    [Abstract] [Full Text] [Related]

  • 14. [Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
    Zhang L, Liu T, Zhang JQ.
    Zhonghua Zhong Liu Za Zhi; 2011 Mar 15; 33(3):212-6. PubMed ID: 21575522
    [Abstract] [Full Text] [Related]

  • 15. Disease-free survival of patients after surgical resection of non-small cell lung carcinoma and correlation with excision repair cross-complementation group 1 expression and genotype.
    Tseden-Ish M, Choi YD, Cho HJ, Ban HJ, Oh IJ, Kim KS, Song SY, Na KJ, Ahn SJ, Choi S, Kim YC.
    Respirology; 2012 Jan 15; 17(1):127-33. PubMed ID: 21899657
    [Abstract] [Full Text] [Related]

  • 16. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
    Shi Y, Chen L, Li J, Lü YL, Jiao SC.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug 15; 32(4):375-82. PubMed ID: 20868593
    [Abstract] [Full Text] [Related]

  • 17. Expression of excision repair cross-complementation group 1, breast cancer susceptibility 1, and β III-tubulin in thymic epithelial tumors.
    Kaira K, Serizawa M, Koh Y, Miura S, Kaira R, Abe M, Nakagawa K, Ohde Y, Okumura T, Naito T, Murakami H, Takahashi T, Kondo H, Nakajima T, Endo M, Yamamoto N.
    J Thorac Oncol; 2011 Mar 15; 6(3):606-13. PubMed ID: 21289518
    [Abstract] [Full Text] [Related]

  • 18. Combined analysis of mRNA expression of ERCC1, BAG-1, BRCA1, RRM1 and TUBB3 to predict prognosis in patients with non-small cell lung cancer who received adjuvant chemotherapy.
    Leng XF, Chen MW, Xian L, Dai L, Ma GY, Li MH.
    J Exp Clin Cancer Res; 2012 Mar 23; 31(1):25. PubMed ID: 22439756
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
    Pesta M, Kulda V, Fiala O, Safranek J, Topolcan O, Krakorova G, Cerny R, Pesek M.
    Anticancer Res; 2012 Nov 23; 32(11):5003-10. PubMed ID: 23155271
    [Abstract] [Full Text] [Related]

  • 20. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer.
    Koh Y, Jang B, Han SW, Kim TM, Oh DY, Lee SH, Kang CH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Kim YW, Kim JH, Heo DS, Bang YJ.
    J Thorac Oncol; 2010 Mar 23; 5(3):320-5. PubMed ID: 20087230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.